Recent findings unveiled at the European Congress on Obesity (ECO) in Istanbul (May 12–15) have sparked a significant shift in how the medical community approaches the treatment of obesity. By moving away from a “one-size-fits-all” model, researchers are now highlighting that the biological impact of obesity is fundamentally sex-dependent.
The study, conducted by a dedicated team at Dokuz Eylul University in Turkey, provides compelling evidence that the physiological manifestations of metabolic syndrome—a precursor to heart disease and type 2 diabetes—diverge sharply between men and women. These insights suggest that the future of metabolic medicine may lie in personalized, gender-specific therapies that address the unique ways in which male and female bodies process fat, inflammation, and hormonal signaling.
Main Facts: A New Perspective on Metabolic Health
Obesity is no longer viewed simply as an issue of total body mass. It is a complex, chronic, and systemic disease that alters how the body manages energy, inflammation, and organ function. The new research demonstrates that while both sexes face severe risks, the "pathway" to these risks differs significantly.
For men, the danger is largely centralized. The study found that men are significantly more prone to accumulating visceral fat—the dangerous adipose tissue that wraps around vital internal organs. This distribution is a primary driver of cardiovascular strain and metabolic disruption. Furthermore, men showed elevated levels of liver enzymes, indicating a higher susceptibility to non-alcoholic fatty liver disease and associated hepatic complications.
In contrast, the female cohort presented a different clinical profile. Women living with obesity were more likely to exhibit systemic inflammation and elevated cholesterol profiles. This suggests that for women, the primary physiological threat from obesity may be rooted in an overactive inflammatory response and dysregulated lipid metabolism, which collectively accelerate the risk of cardiovascular events and insulin resistance.
Chronology of the Research
The investigation, led by Dr. Zeynep Pekel and her colleagues at the Dokuz Eylul University Faculty of Medicine, took place between 2024 and 2025. The study was structured as a cross-sectional analysis, capturing a detailed snapshot of patients currently undergoing treatment at the university’s specialized Obesity Clinic.
- Data Collection (2024–2025): The team recruited 1,134 participants—886 women (average age 45) and 248 men (average age 41).
- Multidimensional Assessment: Participants underwent a rigorous battery of tests, including physical examinations (height, weight, BMI, waist circumference, and blood pressure) and extensive blood analysis to measure lipid profiles, kidney function, liver health, and inflammatory markers.
- Comparative Analysis: Researchers mapped the biomarkers against the participants’ biological sex to identify statistically significant patterns.
- Presentation (May 2025): The final data set, indexed as abstract 1854, was formally presented to global health experts at the European Congress on Obesity in Istanbul.
Supporting Data: By the Numbers
The evidence presented by Dr. Pekel’s team relies on distinct biomarkers that illustrate the divergence in disease progression.
Cardiovascular and Metabolic Indicators
- Waist Circumference: Despite men having a slightly higher average BMI (37.5 vs. 36 kg/m²), their waist circumference was notably larger at 120 cm, compared to 108 cm in women. This reinforces the prevalence of abdominal obesity in males.
- Blood Pressure: Men recorded higher systolic blood pressure (128 mmHg) compared to women (122 mmHg), further elevating their immediate cardiovascular risk profile.
Liver and Kidney Function
Men exhibited significantly higher levels of alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT), both of which are critical indicators of liver stress and potential tissue damage. Creatinine levels—a measure of kidney health—were also higher in men, suggesting that the metabolic load of obesity impacts the renal system differently in males.
Inflammatory and Lipid Profiles
The female participants displayed higher total cholesterol (215 mg/dL vs. 203 mg/dL) and higher LDL (bad) cholesterol (130 mg/dL vs. 123 mg/dL). Perhaps most tellingly, women showed higher concentrations of inflammatory markers, including C-reactive protein (CRP), platelet counts, and elevated erythrocyte sedimentation rates. These findings indicate that while men suffer more from “structural” organ-related fat storage, women suffer more from “biochemical” systemic inflammation.
Official Responses: The Need for Targeted Medicine
"Our findings reveal intriguing differences in the way men and women respond to obesity," said lead author Dr. Zeynep Pekel. She emphasized that these findings are not merely academic; they are a clarion call for a shift in clinical practice.
"Gender-specific research is not just an elective area of study; it is a fundamental requirement for modern medicine," Dr. Pekel noted during the presentation. "Not only are sex differences a powerful player in the pathology and course of obesity, but our results indicate that such differences could be a stepping stone toward finding targeted, sex-based therapies."
The medical community has responded with cautious optimism. Experts agree that if doctors can identify a patient’s risk profile based on their sex—such as screening men more aggressively for liver enzyme imbalances while monitoring women for systemic inflammatory markers—interventions could be significantly more effective.
Implications: A Global Health Challenge
The gravity of these findings is magnified by the current state of global health. As of 2023, approximately 1.54 billion adults worldwide are living with metabolic syndrome. This condition—which includes abdominal obesity, high blood pressure, and high blood glucose—is the engine driving the global epidemic of cardiovascular disease and type 2 diabetes.
Biological Mechanisms
Why do these differences exist? Researchers point to a complex interplay of hormones and genetics:
- The Estrogen Factor: Hormones, particularly estrogen, play a protective role in how fat is distributed and how the body manages inflammation. The loss of this protection, or the fluctuation of these hormones, contributes to the varying ways women store fat and react to weight gain.
- The Immune Response: Women often exhibit a more active immune response, a trait influenced by genetic factors such as the presence of two X chromosomes. While this can provide a robust defense against some pathogens, it may also contribute to the heightened inflammatory markers observed in the study.
- Visceral Fat Accumulation: Men’s biological tendency to store fat in the visceral cavity is a well-documented evolutionary trait, but in the context of modern sedentary lifestyles, it has become a primary driver of metabolic syndrome.
Future Directions and Limitations
The research team is transparent about the study’s limitations. As a cross-sectional study, it cannot establish a definitive cause-and-effect relationship, and the reliance on a primarily Turkish patient base means that future research must expand to more diverse, global populations to ensure these findings hold true across ethnicities.
Despite these limitations, the implications are profound. The next phase of research will focus on validating these results in larger, more varied populations and delving deeper into the molecular mechanisms that drive these sex-based disparities.
For the millions of people living with obesity, this research offers a hopeful glimpse into a future where treatment is no longer a “one-size-fits-all” prescription, but a precise, evidence-based strategy tailored to the unique biology of the individual. As Dr. Pekel concluded, the goal is clear: by understanding the "how" and "why" behind these sex differences, clinicians can move closer to managing, and potentially reversing, the complex health risks associated with obesity.
